What's new

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 17, Status: Authorised

May 23, 2025 - 18:55
 0
Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 17, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab,...

Next Article

Human medicines European public assessment report (EPAR): Advate, octocog alfa, ...

Related Posts

HMA/EMA multi-stakeholder workshop on reporting and qualification of mechanistic models for regulatory assessment, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 October 2025, 10:00 (CEST) to 9 October 2025, 16:10 (CEST)

HMA/EMA multi-stakeholder workshop on reporting and qua...

May 23, 2025  0

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers ...

May 19, 2025  0

Human medicines European public assessment report (EPAR): Maapliv, amino acids, Status: Opinion

Human medicines European public assessment report (EPAR...

May 23, 2025  0